Using a smartphone app to track diet in amyloidosis patients

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This clinical trial aims to investigate malnutrition and weight loss in patients diagnosed with amyloidosis by utilizing a low-cost nutrition-based application called MyFitnessPal. Participants will download the app, complete an online tutorial, and track their daily dietary and supplement intake over a nine-week period. The study will assess the feasibility of this approach in gathering detailed caloric intake data from patients. Additionally, participants will complete questionnaires at various points to evaluate their experience and dietary changes.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* 18 years of age or older
* Diagnosed with any type of amyloidosis
* Speak, read and write in English
* Willing to use the MyFitnessPal app on their own smartphone

Exclusion Criteria:

* a planned autologous stem cell transplant or a solid organ transplant in the 12 weeks after enrollment
* cognitive or perceptual disturbances

Where it's running

• Karmanos Cancer Institute
  Detroit, Michigan, United States Recruiting

Study contacts

• Principal investigator: Jeffrey Zonder, MD — Barbara Ann Karmanos Cancer Institute
• Study coordinator: Jeffrey Zonder, MD
• Email: zonderj@karmanos.org
• Phone: 313-576-8732

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Acoramidis for ATTR-CM: Cardiac Imaging Study

  This study tests whether acoramidis can improve heart structure and function in people with transthyretin amyloid cardiomyopathy.

  Recruiting Phase 4 Eidos Therapeutics, a BridgeBio company · St Louis, Missouri · NCT07695701

• Heart-Healthy Rehab for Cardiac Amyloidosis

  This study tests whether a 5-week supervised cardiac rehabilitation program can help people with cardiac amyloidosis improve exercise capacity and quality of life.

  Recruiting University Hospital, Montpellier · Montpellier · NCT07494942

• SCTC21C plus bortezomib, cyclophosphamide and dexamethasone for newly diagnosed systemic light-chain (AL) amyloidosis

  This trial tests whether adding SCTC21C to standard bortezomib‑cyclophosphamide‑dexamethasone (VCd) helps people with newly diagnosed AL (light‑chain) amyloidosis achieve better hematologic responses and outcomes.

  Recruiting Phase 3 Sinocelltech Ltd. · Beijing, Beijing Municipality · NCT07388602

• In-home cancer treatment with remote specialist support for patients in the Florida Panhandle

  This program will try giving standard cancer treatments at home to people living in the Florida Panhandle and nearby areas to see if they prefer it and have better treatment satisfaction.

  Recruiting Phase 2 Mayo Clinic · Jacksonville, Florida · NCT07285044

• 18F‑FT8 PET imaging for light‑chain (AL) cardiac amyloidosis

  This project tests whether a new PET tracer, 18F‑FT8, can safely and clearly image light‑chain (AL) cardiac amyloidosis in adults with suspected or known disease and in healthy volunteers.

  Recruiting at 3 sites Tianjin Medical University · Hefei, Anhui and 2 other locations · NCT07232459

• Belantamab Mafodotin with a chemotherapy combo for newly diagnosed AL amyloidosis

  This study tests whether adding belantamab mafodotin to a regimen of cyclophosphamide, bortezomib, and dexamethasone can help adults with newly diagnosed AL amyloidosis.

  Recruiting at 16 sites Phase 2 GlaxoSmithKline · Los Angeles, California and 15 other locations · NCT07224672

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.